5月27日，映恩生物-B盘中上涨5.36%，报228.2港元，成交额1.12亿港元。
消息面上，公司于5月26日在公开市场回购3万股股份，耗资约651.44万港元，回购价格介于每股216.20至218.40港元，回购股份以库藏股形式持有。此次回购是公司此前公告的最多4000万美元股份购回计划的落地执行。同时，知名机构LAV Asset Management于5月20日增持公司10.5万股，总金额约2373.92万港元，增持后持股比例升至13.00%。此外，公司创始人朱忠远此前亦宣布拟以自有资金增持不超过500万美元。多重利好信号叠加，市场信心有所修复。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.